Loading...
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials
BACKGROUND: Although the addition of bevacizumab to 1(st )line chemotherapy provides a significant survival benefit for advanced colorectal cancer, the magnitudes of both advantages and toxicities have not been extensively investigated. METHODS: A literature-based meta-analysis was conducted; Hazard...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2010
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2890550/ https://ncbi.nlm.nih.gov/pubmed/20504361 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-9966-29-58 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|